EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Early antibody treatment, inflammation, and risk of post-COVID conditions

Kelly A Gebo, Sonya L Heath, Yuriko Fukuta, Xianming Zhu iD, Sheriza Baksh, Allison G Abraham, Feben Habtehyimer, David Shade, Jessica Ruff, Malathi Ram, Oliver Laeyendecker iD, Reinaldo E Fernandez und 32 weitere

mBio · 2023

DOI: 10.1128/mbio.00618-23 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift mBio, 2023. Verfasst von Kelly A Gebo und 43 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Post-Acute COVID-19 Syndrome, COVID-19. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post-COVID conditions (PCCs) are common and have significant morbidity. Risk factors for PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known about treatment, inflammation, and PCC. Among 882 individuals with confirmed SARS-CoV-2 infection participating in a randomized trial of COVID-19 convalescent plasma (CCP) vs control plasma with available biospecimens and symptom data, the association between early CCP treatment, cytokine levels, and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14, and day 90 using a multiplexed sandwich immunoassay (Meso Scale Discovery). Presence of any self-reported PCC symptoms was assessed at day 90. Associations between CCP treatment, cytokine levels, and PCC were examined using multivariate logistic regression models. One third of the 882 participants had day 90 PCC symptoms, with fatigue (14.5%) and anosmia (14.5%) being most common. Cytokine levels decreased from baseline to day 90. In a multivariable analysis, female sex (adjusted odds ratio [AOR] = 2.69 [1.93–3.81]), older age (AOR = 1.32 [1.17–1.50]), and elevated baseline levels of IL-6 (AOR = 1.59 [1.02–2.47]) were independently associated with development of PCC. Those who received early CCP treatment (≤5 days after symptom onset) compared to late CCP treatment had statistically significant lower odds of PCC. IMPORTANCE Approximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated with PCC or whether early intervention treatments may decrease the risk of PCC. In a secondary analysis of a randomized clinical trial, this study demonstrates that among outpatients with SARS-CoV-2, increased IL-6 at time of infection is associated with increased odds of PCC. In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical characteristics. Future treatment studies should be considered to evaluate the effect of early treatment and anti-IL-6 therapies on PCC development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Post-Acute COVID-19 SyndromeCOVID-19HumansSARS-CoV-2COVID-19 SerotherapyAntibodiesInflammation

Stichwörter der Autor:innen

COVID-19COVID-19 serotherapychemokinescytokinesinterleukin-6post-COVID condition (PCC)post-acute sequelae of COVID (PASC)

Substanzen

Antibodies

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
  • Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham , Birmingham, Alabama, USA.
  • Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine , Houston, Texas, USA.
  • Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
  • Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.
  • Department of Epidemiology, University of Colorado, Anschutz Medical Campus , Aurora, Colorado, USA.

ORCID-Profile: Xianming Zhu, Oliver Laeyendecker, Eshan U Patel, Donald N Forthal, Catherine G Sutcliffe, Sabra L Klein, Andrew Pekosz, Evan M Bloch, Arturo Casadevall, Aaron A R Tobian, David J Sullivan

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • NIDA NIH HHS
  • NIDDK NIH HHS
  • U.S. Department of Defense
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • HHS | NIH | National Institute on Drug Abuse
  • HHS | NIH | National Center for Advancing Translational Sciences

Zitieren

APA

Gebo, K. A., Heath, S. L., Fukuta, Y., Zhu, X., Baksh, S., Abraham, A. G., Habtehyimer, F., Shade, D., Ruff, J., Ram, M., Laeyendecker, O., Fernandez, R. E., Patel, E. U., Baker, O. R., Shoham, S., Cachay, E. R., Currier, J. S., Gerber, J. M., Meisenberg, B., …, & CSSC-004 Consortium (2023). Early antibody treatment, inflammation, and risk of post-COVID conditions. mBio. https://doi.org/10.1128/mbio.00618-23

Vancouver

Gebo KA, Heath SL, Fukuta Y, Zhu X, Baksh S, Abraham AG, et al. Early antibody treatment, inflammation, and risk of post-COVID conditions. mBio. 2023. doi:10.1128/mbio.00618-23

BibTeX
@article{Gebo2023,
  author = {Gebo, Kelly A and Heath, Sonya L and Fukuta, Yuriko and Zhu, Xianming and Baksh, Sheriza and Abraham, Allison G and Habtehyimer, Feben and Shade, David and Ruff, Jessica and Ram, Malathi and Laeyendecker, Oliver and Fernandez, Reinaldo E and Patel, Eshan U and Baker, Owen R and Shoham, Shmuel and Cachay, Edward R and Currier, Judith S and Gerber, Jonathan M and Meisenberg, Barry and Forthal, Donald N and Hammitt, Laura L and Huaman, Moises A and Levine, Adam and Mosnaim, Giselle S and Patel, Bela and Paxton, James H and Raval, Jay S and Sutcliffe, Catherine G and Anjan, Shweta and Gniadek, Thomas and Kassaye, Seble and Blair, Janis E and Lane, Karen and McBee, Nichol A and Gawad, Amy L and Das, Piyali and Klein, Sabra L and Pekosz, Andrew and Bloch, Evan M and Hanley, Daniel and Casadevall, Arturo and Tobian, Aaron A R and Sullivan, David J and CSSC-004 Consortium, CSSC-004 Consortium},
  title = {Early antibody treatment, inflammation, and risk of post-COVID conditions},
  journal = {mBio},
  year = {2023},
  doi = {10.1128/mbio.00618-23}
}
Kostenlos starten →